Live Analyst Rating Changes 21841 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Stephen Willey
STIF

Stephen Willey

Stifel Nicolaus
Wall Street Analyst
★★☆☆☆
#2192
on 13Foresight · ranked by our own returns
52%
Success Rate
+2.9%
Average Return
33 of 64 calls profitable · -2.8% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 52% of Stephen Willey's ratings turned a profit when each position was held for 1 year — averaging +2.9% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

114 Buy 14 Hold 0 Sell
Stephen's Stock Coverage 48 ratings · 2026-08-10
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
OABI
OmniAb
 Aug 07, 2026 BUY Strong Buy
+147.5% avg upside
10 analysts
$9.00
176.11% Upside
 +0.0% ·
JANX
Janux Therapeutics Inc
 Aug 07, 2026 BUY Strong Buy
+191.2% avg upside
21 analysts
$35.00
114.18% Upside
 +0.0% ·
ZYME
Zymeworks
 Aug 07, 2026 BUY Strong Buy
+39.5% avg upside
25 analysts
$46.00
91.12% Upside
 · ·
EXEL
Exelixis
 Aug 06, 2026 HOLD Buy
-18.9% avg upside
34 analysts
$51.00
3.47% Downside
 +1.4% ·
LYEL
Lyell Immunopharma
 Aug 06, 2026 BUY Strong Buy
+89.3% avg upside
12 analysts
$36.00
149.56% Upside
 +0.8% ·
ABCL
AbCellera Biologics
 Aug 06, 2026 BUY Strong Buy
+82.8% avg upside
15 analysts
$9.00
2.32% Downside
 +6.1% ·
CBIO
Crescent Biopharma
 Jul 31, 2026 BUY Strong Buy
+31.7% avg upside
17 analysts
$28.00
62.41% Upside
 +16.4% ·
IRON
Disc Medicine
 Jul 31, 2026 BUY Strong Buy
+12.2% avg upside
21 analysts
$111.00
43.18% Upside
 +0.6% ·
INCY
Incyte
 Jul 28, 2026 BUY Buy
-11.1% avg upside
47 analysts
$145.00
18.63% Upside
 -7.2% ·
MGNX
MacroGenics
 Jul 24, 2026 HOLD Buy
+335.6% avg upside
25 analysts
$4.00
2.02% Downside
 -0.3% ·
INSM
Insmed
 Jul 17, 2026 BUY Strong Buy
+33.8% avg upside
37 analysts
$200.00
49.94% Upside
 +24.4% ·
SNDX
Syndax Pharmaceuticals
 Jul 15, 2026 BUY Strong Buy
+74.7% avg upside
27 analysts
$46.00
125.25% Upside
 -13.3% ·
CELC
Celcuity
 Jul 15, 2026 BUY Strong Buy
+34.7% avg upside
16 analysts
$175.00
90.70% Upside
 +1.4% ·
CADL
Candel Therapeutics
 Jul 13, 2026 BUY Strong Buy
+72.8% avg upside
11 analysts
$22.00
111.48% Upside
 +9.8% ·
NRIX
Nurix Therapeutics
 Jul 10, 2026 BUY Strong Buy
+26.0% avg upside
28 analysts
$40.00
55.95% Upside
 +9.4% ·
PYXS
Pyxis Oncology
 Jul 02, 2026 BUY Strong Buy
+95.0% avg upside
14 analysts
$8.00
103.07% Upside
 +41.8% ·
CMPX
Compass Therapeutics
 Jun 01, 2026 BUY Strong Buy
+342.8% avg upside
20 analysts
$6.00
178.41% Upside
 -0.7% ·
NKTX
Nkarta
 May 13, 2026 BUY Strong Buy
+673.7% avg upside
16 analysts
$11.00
346.22% Upside
 -21.2% ·
BCAX
Bicara Therapeutics Inc.
 May 12, 2026 BUY Strong Buy
+11.2% avg upside
14 analysts
$46.00
64.21% Upside
 +25.4% ·
VOR
Vor Biopharma
 Apr 08, 2026 BUY Buy
+83.6% avg upside
17 analysts
$40.00
69.75% Upside
 +50.6% ·
ABEO
Abeona Therapeutics
 Mar 18, 2026 BUY Strong Buy
+136.5% avg upside
17 analysts
$17.00
138.11% Upside
 +59.1% ·
XFOR
X4 Pharmaceuticals
 Nov 05, 2025 BUY Strong Buy
+423.7% avg upside
16 analysts
$7.50
67.35% Upside
 +30.7% ·
GYRE
Gyre Therapeutics
 Jun 24, 2025 BUY Strong Buy
+211.6% avg upside
15 analysts
$28.00
326.09% Upside
 -14.8% ·
BOLT
Bolt Biotherapeutics
 May 13, 2025 HOLD Buy
+542.6% avg upside
7 analysts
$20.00
396.93% Upside
 -30.0% ·
GERN
Geron
 Mar 12, 2025 BUY Strong Buy
+189.2% avg upside
19 analysts
$4.00
169.33% Upside
 -9.6% ·
CUE
Cue Biopharma
 Nov 15, 2024 BUY Strong Buy
-65.1% avg upside
9 analysts
$4.00
84.81% Downside
 -49.4% ·
CGEN
Compugen
 Nov 06, 2024 BUY Strong Buy
+126.8% avg upside
8 analysts
$4.00
69.43% Upside
 -4.7% ·
LITS
Lite Strategy
 May 14, 2024 HOLD Buy
+1141.0% avg upside
13 analysts
$6.00
578.73% Upside
 -29.8% ·
SQZB
SQZ Biotechnologies
 Aug 11, 2022 BUY Buy
+102677.8% avg upside
7 analysts
$14.00
58233.31% Upside
 · ·
SPRY
ARS Pharmaceuticals
 May 13, 2022 HOLD Strong Buy
+251.0% avg upside
12 analysts
$5.00
15.37% Downside
 +171.6% ·
IVVD
Invivyd
 May 13, 2022 HOLD Buy
+1019.6% avg upside
8 analysts
$5.00
617.95% Upside
 -47.1% ·
INO
Inovio Pharmaceuticals
 May 11, 2022 HOLD Buy
+1167.0% avg upside
19 analysts
$1.00
42.72% Upside
 -56.9% ·
SPRO
Spero Therapeutics
 Mar 12, 2021 BUY Buy
+991.8% avg upside
12 analysts
$27.00
2060.00% Upside
 -50.1% ·
LXRX
Lexicon Pharmaceuticals
 Mar 11, 2021 HOLD Buy
+63.3% avg upside
9 analysts
$6.00
148.88% Upside
 -69.9% ·
XENE
Xenon
 Mar 29, 2019 BUY Strong Buy
-1.8% avg upside
28 analysts
$21.00
66.80% Downside
 +8.3% ·
TARA
Protara Therapeutics
 Mar 14, 2019 HOLD Strong Buy
+1163.2% avg upside
21 analysts
$160.00
3802.46% Upside
 · ·
IONS
Ionis Pharmaceuticals
 Aug 06, 2018 HOLD Strong Buy
+39.4% avg upside
43 analysts
$48.00
16.20% Downside
 +46.8% ·
BMRN
BioMarin Pharmaceutical
 Aug 06, 2018 BUY Strong Buy
+47.1% avg upside
52 analysts
$114.00
73.24% Upside
 -22.4% ·
ALNY
Alnylam Pharma
 Aug 06, 2018 BUY Strong Buy
+47.6% avg upside
51 analysts
$125.00
42.48% Downside
 -20.1% ·
INVA
Innoviva
 Apr 27, 2018 HOLD Buy
+40.1% avg upside
12 analysts
$16.00
22.67% Downside
 -3.2% ·
GNCAQ
Genocea Biosciences
 Sep 26, 2017 HOLD Strong Buy
+573999900.0% avg upside
10 analysts
$2.50
249999900.06% Upside
 · ·
HCM
HUTCHMED
 Apr 04, 2017 BUY Strong Buy
+145.6% avg upside
9 analysts
$26.00
108.13% Upside
 +55.0% ·
TVRD
Tvardi Therapeutics
 Feb 02, 2017 BUY Buy
+883.9% avg upside
23 analysts
$24.00
1263.54% Upside
 · ·
RNAC
Cartesian Therapeutics
 Dec 02, 2016 BUY Strong Buy
+259.1% avg upside
19 analysts
$23.00
163.39% Upside
 · ·
JAZZ
Jazz Pharmaceuticals
 May 31, 2016 BUY Strong Buy
-8.0% avg upside
35 analysts
$200.00
22.01% Downside
 -4.0% ·
ACHV
Achieve Life Sciences
 Dec 02, 2015 HOLD Strong Buy
+134.1% avg upside
14 analysts
 — · ·
ABUS
Arbutus Biopharma
 Nov 07, 2014 BUY Strong Buy
+91.6% avg upside
15 analysts
$26.00
466.37% Upside
 -64.6% ·
RIGL
Rigel
 Apr 08, 2013 BUY Strong Buy
-39.9% avg upside
17 analysts
$7.00
82.96% Downside
 -24.7% ·
🔒 43 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Stephen Willey — Frequently Asked Questions
How accurate are Stephen Willey's stock ratings?
Based on the calls 13Foresight could measure, about 50% of Stephen's ratings were profitable over a one-year hold, with an average return of +2.9% per rating, or -2.8% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Stephen ranked on 13Foresight?
Stephen Willey is currently ranked #2192 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Stephen cover?
Stephen most recently has ratings on OABI, JANX, ZYME, EXEL, LYEL, ABCL, CBIO, IRON, INCY, MGNX, INSM, SNDX and 36 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.